Skip to main content
SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. logo

SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 688163 ISIN · CNE1000059X8 LEI · 8368001TREMN2G5DDS70 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 335 across all filing types
Latest filing 2025-06-18 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688163

About SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD.

https://www.serum-china.com.cn/en/

Shanghai Serum Bio-Technology Co., Ltd. is a specialized biopharmaceutical enterprise focused on the research, development, and manufacturing of therapeutic biological products. The company primarily produces a range of antiserums and antitoxins, including specialized antivenoms for various snake species, tetanus antitoxins, and rabies immunoglobulins. Its product portfolio supports emergency medical care and infectious disease management. The organization maintains advanced production facilities compliant with Good Manufacturing Practice (GMP) standards to ensure the safety and efficacy of its biological treatments. By leveraging biotechnological innovation, the company serves clinical needs in healthcare sectors, providing critical life-saving interventions for envenomation and acute bacterial toxins.

Recent filings

Filing Released Lang Actions
赛伦生物：关于部分募集资金投资项目结项并将节余募集资金永久补充流动资金以及注销相关募集资金专户的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shanghai SAILUN Biotech Co., Ltd. regarding the completion of a fundraising investment project and the permanent supplementation of surplus raised funds into working capital, along with the cancellation of the related fundraising special account. It details the use and surplus of funds raised from the company's initial public offering (IPO), including specific project completion status and financial figures related to the fundraising. The document is a formal announcement about the status and use of raised capital rather than a full financial report or audit. It does not contain comprehensive financial statements or detailed financial performance data. The document length is 2568 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this fits best under the category of Capital/Financing Update (CAP), as it updates on the use and status of fundraising capital and related financial arrangements.
2025-06-18 Chinese
赛伦生物：2024年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement from Shanghai SAILUN Biotechnology Co., Ltd. regarding the implementation of the 2024 annual dividend distribution. It details the dividend per share, relevant dates (record date, ex-dividend date, payment date), the shareholder meeting approval date, tax treatment for different shareholder categories, and contact information for inquiries. The document does not contain financial statements or comprehensive financial analysis but focuses solely on the dividend distribution details. The document length is 2481 characters, which is relatively short and typical for a dividend announcement. Therefore, this document fits the category of Notice of Dividend Amount (DIV).
2025-05-27 Chinese
方正证券承销保荐有限责任公司关于上海赛伦生物技术股份有限公司2024年度持续督导跟踪报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2024年度持续督导跟踪报告" (2024 Annual Continuous Supervision Follow-up Report) issued by 方正证券承销保荐有限责任公司, the sponsor institution for 上海赛伦生物技术股份有限公司. It references regulatory frameworks related to securities issuance and listing supervision, and details the continuous supervision activities, risk factors, financial data, core competencies, R&D progress, and compliance with fundraising usage. The document contains substantive financial data, detailed management oversight, and compliance information for the fiscal year 2024. It is not a full annual report (10-K) but a specialized supervisory follow-up report by the sponsor institution, which aligns with the definition of an Audit Report / Information (AR) as it relates to audit and regulatory supervision reports excluding full annual reports. The document is over 13,000 characters, so it is not a mere announcement. It is not a management report (MDA) or regulatory filing (RNS) because it contains detailed supervisory and audit-related content. Therefore, the best classification is AR (Audit Report / Information). FY 2024
2025-05-20 Chinese
上海赛伦生物技术股份有限公司2024年年度股东大会法律意见书
Regulatory Filings
2025-05-16 Chinese
赛伦生物：2024年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2024 Annual General Meeting (AGM) of Shanghai SAILUN Biotechnology Co., Ltd. It includes information about the meeting date, attendance, voting results on various proposals including the annual report, financial statements, profit distribution, remuneration, and auditor appointment. The document also contains legal opinions confirming the validity of the meeting and resolutions. The content is focused on the official voting results and decisions made at the AGM rather than the full annual report or financial statements themselves. The document length is 4107 characters, which is relatively short and typical for a voting results announcement. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-05-16 Chinese
赛伦生物：2024年年度股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as "2024 年年度股东大会会议资料" which translates to "2024 Annual General Meeting (AGM) Meeting Materials". It contains detailed agenda, reports, and proposals to be discussed and voted on at the 2024 Annual General Meeting of Shanghai Sairen Biotechnology Co., Ltd. The content includes the board of directors' work report, supervisory board report, financial statements, profit distribution plans, remuneration proposals, and other AGM-related materials. The document is comprehensive and clearly intended as the presentation and materials shared during the AGM, not just an announcement or a brief summary. Therefore, it fits the category of AGM Information (AGM-R).
2025-05-08 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.